Therapy Areas: Central Nervous System
UCB Study Provides Insights about Women with Chronic Rheumatic Diseases During Pregnancy
19 June 2018 - - Brussels, Belgium-based biopharmaceutical company UCB (Euronext Brussels: UCB) has presented findings from a patient survey entitled "Fears and Misconceptions of Women with Chronic Rheumatic Diseases Along Their Journey to Motherhood" at the Annual European Congress of Rheumatology (EULAR 2018), the company said.
A total of 1,052 women living with chronic inflammatory diseases were surveyed across Europe (Germany, France, UK, Italy and Spain), the US and Japan. Results presented at EULAR 2018 specifically highlight the experience of women aged 18-45 living with chronic rheumatic diseases (622/1052 participants), including axial spondyloarthritis (axSpA), psoriatic arthritis, and rheumatoid arthritis.
Findings from 622 women across Europe, the US, and Japan with chronic rheumatic diseases, including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (axSpA), suggest that women with chronic rheumatic diseases face unique challenges during their childbearing years that may be linked to decisions to delay pregnancy and interrupt treatment, and that many women of childbearing age with chronic rheumatic diseases experience a lack of guidance and consistent information regarding family planning and treatment during their pregnancy journey and breastfeeding.
Survey findings point to a need for greater awareness of disease management options, earlier consultation with physicians and alignment on best care to optimize outcomes for mother and infant, and a need for greater access to reliable and consistent information.
To support women living with chronic rheumatic diseases as they navigate their childbearing years, UCB is launching the AIM Movement, a global campaign with local reach designed to spread awareness about managing chronic rheumatic diseases throughout all stages of reproductive journey and encourage women to have informed conversations with their healthcare professionals.
UCB is focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7,500 people in approximately 40 countries, the company generated revenue of EUR 4.5bn in 2017.
Login
Username:

Password: